Date: 2017-05-15
Type of information: Restructuring
Compound:
Company: Takeda Pharmaceutical (Japan) Bushu Pharmaceuticals (Japan) Spera Pharma (Japan)
Therapeutic area:
Type agreement: restructuring
Action mechanism:
Disease:
Details:
- • On May 15, 2017, Takeda Pharmaceutical announced that it has entered into an agreement for an absorption-type company split with its wholly-owned subsidiary, Spera Pharma, that was established in April 2017, aiming to transfer a part of Takeda's Pharmaceutical Sciences/CMC businesses to Bushu Pharmaceuticals.
- Takeda will transfer all of the issued shares in Succeeding Company to Bushu based on a share transfer agreement signed on February 28, 2017. As Takeda’s strategic partner, Bushu will deliver on process chemistry, formulation and analytical development, as well as development, manufacturing and associated work of clinical trial materials. Takeda is in the process of implementing steps to accelerate its research and development (R&D) transformation by refocusing on three key therapeutic areas – Oncology, Gastroenterology and Central Nervous System, plus Vaccines, and concentrating R&D activities in Japan and the U.S. This transformation is critical to provide the company with the necessary organizational and financial flexibility to drive innovation, enhance partnerships, and improve R&D productivity for long-term, sustainable growth. As a part of this initiative, Takeda entered into a pharmaceutical sciences partnership agreement with Bushu in February 2017. This partnership, which enables a more agile and flexible approach for clinical trial material development and manufacturing, will allow Takeda to improve its operating efficiencies and create a more agile organization to better meet patient needs. Subsequent to the company split, all of the issued shares in Spera Pharma will be transferred to Bushu. Through this share transfer, will be a wholly-owned subsidiary of Bushu, which is scheduled to be effective as of July 1, 2017.
Financial terms:
Latest news:
Is general: Yes
